MW AstraZeneca to pay up to $2 billion to license cardiovascular drug
By Steve Goldstein
AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.
The Anglo-Swedish company $(AZN)$ (UK:AZN) said it will pay $100 million upfront plus up to $1.9 billion in milestone payments to CSPC Pharmaceutical Group (HK:1093) to license a pre-clinical candidate small molecule, to develop as a novel lipid-lowering therapy.
That's meant in particular to treat patients with dyslipidaemia.
The molecule has been shown to effectively prevent the formation of what's Lp(a), a form of low-density lipoprotein that helps transport cholesterol in the blood stream.
In its own release, CSPC said it's eligible to get up to $370 million in potential development milestone payments and up to $1.55 billion in potential sales milestone payments, as well as tiered royalties based on annual sales.
CSPC said the compound was discovered by the Group's AI-driven small molecule drug design platform.
AstraZeneca's London-listed shares slipped 0.2% on Monday but have gained 11% this year. CSPC stock jumped 5% on Monday but is down 2% this year.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
October 07, 2024 04:58 ET (08:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.